| 2026/05/07 | 15:41:07 | Medeon, on behalf of its subsidiary Medeologix Corporation, announces the resolution of BOD on the issuance of common shares. | |
| SEQ_NO |
2 |
Date of announcement |
2026/05/07 |
Time of announcement |
15:41:07 |
| Subject |
Medeon, on behalf of its subsidiary Medeologix Corporation, announces the resolution of BOD on the issuance of common shares. |
| Date of events |
2026/05/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2026/05/07
2.Source of capital increase funds:
Issuance of common shares through a cash capital increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GNT$162,000,000
Number of shares issued?G6,000,000 Common Shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:NA
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:NA
7.Par value per share:NT$10
8.Issue price: NT$27
9.Number of shares subscribed for by or allocated to employees:
10% of the total issued shares, amounting to 600,000 shares, are reserved
for subscription by the Medeologix Corporation’s employees.
10.Number of shares publicly sold:NA
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
The remaining number of shares to be issued will be subscribed in
proportion to the shareholders and their shareholdings as recorded in
the shareholders’ register on the basis of the subscription date.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
Any shares forfeited by existing shareholders or employees, and any
fractional shares resulting from insufficient aggregation, shall be
subscribed by specific persons designated by the Chairman at the issue
price.
13.Rights and obligations of these newly issued shares:
The rights and obligations of the new shares issued in this cash capital
increase are identical to those of the originally issued common shares.
14.Utilization of the funds from the capital increase:
For the purpose of increasing working capital.
15.Any other matters that need to be specified:None |
|
| 2026/05/07 | 15:26:16 | Announcement of a statutory merger between Medeologix Corporation’s wholly owned subsidiaries Medeologix LLC and Medeologix, Inc. | |
| SEQ_NO |
1 |
Date of announcement |
2026/05/07 |
Time of announcement |
15:26:16 |
| Subject |
Announcement of a statutory merger between Medeologix Corporation’s wholly owned subsidiaries Medeologix LLC and Medeologix, Inc. |
| Date of events |
2026/05/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Type of merger and acquisition (e.g.merger, spin-off , acquisition,
or share transfer):Merger
2.Date of occurrence of the event:2026/05/07
3.Names of companies participating in the merger and acquisition
(e.g., name of the other company participating in
the merger, newly established company in a spin-off,
acquired company, or company whose shares are transferred):
Surviving company: Medeologix LLC
Dissolved company: Medeologix, Inc.
4.Trading counterparty (e.g., name of the other company
participating in the merger, company spinning off, or trading
counterparty to the acquisition or share transfer):
Same as above.
5.Whether the counterparty of the current transaction is a
related party:Yes
6.Relationship between the trading counterparty and the Company
(investee company in which the Company has re-invested and has
shareholding of XX%), explanation of the reasons for the
decision to acquire from or transfer shares to an affiliated
enterprise or related party, and whether it will affect
shareholders’ equity:
Both the surviving company, Medeologix LLC, and the dissolved company,
Medeologix, Inc., are wholly owned subsidiaries of Medeologix Corporation.
The merger will not affect the rights and interests of the Company’s
shareholders.
7.Purpose and conditions of the merger and acquisition, including
the reason, consideration conditions and payment schedule of the
merger and acquisition:
The merger is intended to consolidate the resources of the Group, and will
be implemented through a statutory merger in accordance with the laws of
California.
8.Anticipated benefits of the merger and acquisition:
The merger is expected to enhance operational efficiency and reduce
management costs.
9.Effect of the merger and acquisition on net worth per share
and earnings per share:None.
10.Types of consideration for mergers and acquisitions and sources
of funds:N/A
11.Share exchange ratio and calculation assumptions:N/A
12.Whether the CPA, lawyer or securities underwriter issued an
opinion on the unreasonableness regarding the transaction:N/A
13.Name of accounting, law or securities firm:N/A
14.Name of CPA or lawyer:N/A
15.Number of CPA or lawyer license:N/A
16.The content of the independent expert opinion on the
reasonableness of the share exchange ratio, cash or other
assets allotted to shareholders in this merger and acquisition
(1.The method, principles, or calculations adopted for
determination of the public tender offer price, and comparison
with the market-value method, cost method, and discounted cash
flow method commonly used internationally; 2.comparison of the
financial condition, profit status, and price-to-earnings
ratio of the subject company with those of TWSE or TPEx listed
companies in the same industry; 3.if a price appraisal report
of an appraisal organization is taken into account in the public
tender offer price, the opinion shall specify the content and
conclusion of the appraisal report; and 4.if assets or shares
of the subject company, or of the surviving company in the
case of a merger, are listed as collateral in the tender
offeror’s financing repayment plan, the opinion shall disclose
the collateralization terms, and assessment of the impact on
the financial and operational soundness, of the subject company
or of the surviving company of the merger.):N/A
17.Estimated date of completion:
The tentative merger record date is May 26, 2026.
18.Matters related to the assumption of corporate rights and
obligations of the dissolving company (or spin-off) by the
existing or newly-established company:
Upon completion of the merger, the Surviving company, Medeologix LLC,
will acquire all assets, rights, and liabilities of the Dissolved company,
Medeologix, Inc.
19.Basic information of companies participating in the merger:
Surviving company: Medeologix LLC , principally engaged in the manufacture
and sale of medical devices.
Dissolved company: Medeologix, Inc. , principally engaged in the
manufacture and sale of medical devices.
20.Matters related to the spin-off (including estimated value
of the business and assets planned to be transferred to the
existing company or new company.The total no.of shares to
be acquired by the spun-off company or its shareholders, and
their respective types and no.Matters related to the reduction,
if any, in capital of the spun-off company) (note: not applicable
for announcements unrelated to spin-offs):N/A
21.Conditions and restrictions for future transfer of shares
resulting from the merger and acquisition:N/A
22.Post-merger and acquisition plan: (1) Willingness to continue
operating the business of the company, and the contents of
plans to that effect (2) Dissolution; delisting from an exchange
(or OTC market); material changes in organization, capital,
business plan, financial operations and production; accommodation
or utilization of staff and assets critical to the Company; or
any other matter of material significance that would affect the
company’s shareholder equity:None
23.Other important terms and conditions:None
24.Other major matters related to the mergers and acquisitions:None
25.Any objections from directors to the transaction:None
26.Information on interested directors involved in the mergers
and acquisitions (name of natural person director or name of
legal person director and its representative, material
interest of the director or the legal person represented by
the director (including but not limited to form of actual
or expected investment in another company in the merger,
shareholding, transaction price, participation in the subject
company’s business or otherwise, and other terms of
investment), reason for recusal or otherwise, details of
recusal, and reason for a resolution for or against the merger
proposal):None
27.Is it related to new business model ?:No
28.Explanation of new business model:N/A
29.Transactions with the counterparty for the past one year
and the next year:N/A
30.Source of funds:N/A
31.Any other matters that need to be specified:
The merger record date is tentatively set as May 26, 2026, and the
Chairman is authorized to adjust the actual merger record date in
accordance with applicable regulations and operational needs. |
|
| 2026/04/30 | 17:38:49 | Announcement of the Board of Directors Meeting Date for Approval of the First-Quarter 2026 Financial Report | |
| SEQ_NO |
1 |
Date of announcement |
2026/04/30 |
Time of announcement |
17:38:49 |
| Subject |
Announcement of the Board of Directors Meeting Date for Approval of the First-Quarter 2026 Financial Report |
| Date of events |
2026/04/30
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of a notice of the board of directors meeting is issued:2026/04/30
2.Expected date of the board of directors meeting is convened:2026/05/08
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors: First-Quarter 2026
4.Any other matters that need to be specified:None |
|
| 2026/03/23 | 14:35:29 | The Company has been required by TPEx to announce the financial data according to the regulations. | |
| SEQ_NO |
1 |
Date of announcement |
2026/03/23 |
Time of announcement |
14:35:29 |
| Subject |
The Company has been required by TPEx to announce the financial data according to the regulations. |
| Date of events |
2026/03/23
|
To which item it meets |
paragraph 53 |
| Statement |
1.Date of occurrence of the event: 2026/03/23
2.Cause of occurrence:Announced as required by the TPEx
3.Financial and business information:
Unit: (NT$million)
(1) Monthly
Feb 2026 Feb 2025 YoY Change %
————————————————————————–
Sales revenue 47.9 36.2 32.3% (Revenue increased)
Loss before income tax (39.4) (63.8) 38.2% (Losses reduced)
Net Loss attributable to
Owners of the parent (35.5) (59.4) 40.2% (Losses reduced)
EPS (NT$) (0.4) (0.6) 43.1% (Losses reduced)
==========================================================================
(2)Quarterly
Q4 2025 Q4 2024 YoY Change %
————————————————————————–
Sales revenue 114.9 77.3 48.5% (Revenue increased)
Loss before income tax (154.7) (225.9) 31.5% (Losses reduced)
Net Loss attributable to
Owners of the parent (137.1) (208.8) 34.3% (Losses reduced)
EPS (NT$) (1.5) (2.3) 34.5% (Losses reduced)
==========================================================================
(3)Cumulative for the last four seasons
Latest 4 quarters accumulation
(Q1 2025 to Q4 2025)
————————————————————————–
Revenue 419.4
Loss before income tax (719.7)
Net Loss attributable to
Owners of the parent (668.1)
EPS (NT$) (7.2)
==========================================================================
4.Any material information that needs to be specified
according to Article 4 of Taipei Exchange Procedures
for Verification and Disclosure of Material Information
of Companies with TPEx Listed Securities:
Medeon has disclosed material information titled ‘Urocross Expander
System Officially Obtained U.S. FDA 510(k) Clearance’ in accordance
with Article 53 over the past six business days.
5.Any material information in a press conference listed
under Article 11 of Taipei Exchange Procedures for
Verification and Disclosure of Material Information of
Companies with TPEx Listed Securities:
Medeon has not held any press conferences to explain material information
in the past six business days.
6.Any other matters that need to be specified:
(1)The aforementioned financial information for February 2026 and its YOY
comparison consists in the consolidated reviewed amounts prepared by
the Company adopting the IFRS, and has not been audited (reviewed) by
CPA. This information is provided for investors’ reference only.
(2)The information for the latest quarter (Q4 2025) refers to single
quarter amounts, not cumulative amounts from the latest financial
reports, and are consolidated amounts prepared under the IFRS, which
have been audited (reviewed) by CPA. This information is provided for
investors’ reference only.
(3)The information accumulated over the last 4 quarters consists in the
consolidated amounts from Q1 2025 to Q4 2025 prepared by the Company
adopting the IFRS, and has been audited (reviewed) by CPA. This
information is provided for investors’ reference only. |
|
| 2026/03/13 | 16:44:17 | Urocross Expander System Officially Obtained U.S. FDA 510(k) Clearance | |
| SEQ_NO |
1 |
Date of announcement |
2026/03/13 |
Time of announcement |
16:44:17 |
| Subject |
Urocross Expander System Officially Obtained U.S. FDA 510(k) Clearance |
| Date of events |
2026/03/13
|
To which item it meets |
paragraph 10 |
| Statement |
1.Date of occurrence of the event:2026/03/13
2.New drug name or code:Urocross Expander System
3.Indication:
The Urocross Expander System is a retrievable, non-permanent implant
system developed to improve lower urinary tract symptoms (LUTS)
associated with Benign Prostatic Hyperplasia (BPH). The system gently
expands the prostatic urethral tissue through a minimally invasive
procedure performed under mild anesthesia, thereby relieving obstruction
and improving urinary flow.
4.Planned development stages:
The Urocross Expander System has officially obtained the 510(k) Clearance
from the U.S. FDA on 2026/03/13 (Taipei Time).
5.Current development stage:
(1) Submission of application / approval granted / approval not granted /
results of each phase of clinical trials (including interim analysis)
/ occurrence of other material events affecting new drug development:
The Urocross Expander System has officially obtained the U.S. FDA for
510(k) Clearance
(2) In the event that approval is not granted by the competent authority
for the intended use, or the results of any phase of clinical trials
(including interim analysis) fail to reach statistical significance,
or other material events occur that may affect new drug development,
the risks faced by the Company and corresponding countermeasures:
Not Applicable
(3) In the event that approval has been granted by the competent authority
for the intended use, or the results of any phase of clinical trials
(including interim analysis) reach statistical significance, or other
material events occur that may affect new drug development, the
Company’s future business plans and directions:
Not Applicable
(4) Cumulative research and development expenses incurred?G
Due to the involvement of information pertaining to future
international licensing negotiations, and to avoid impacting the deal
amount while safeguarding the rights and interests of investors, the
details will not be disclosed at this time.
6.Upcoming development plan:
Subsequent efforts will continue to advance preparations for product
launch while simultaneously conducting international strategic
collaboration discussions.
7.Market situation:
The probability of men suffering from BPH increases with age. The
estimated population in only the United States with BPH is reaching 40
million. As the population continues to age, the number of BPH patients
is expected to grow accordingly. According to a market research report by
Grand View Research, the global market for medical devices treating BPH
reached USD 1.67 billion in 2024. It is projected that from 2025 to 2033,
the BPH-related market will grow at a compound annual growth rate (CAGR)
of 9.4%, reaching USD 3.71 billion in 2033.
8.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 8
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
The Company has successfully obtained 510(k) clearance, enabling it to
legally commence sales activities in the U.S. market. Commercialization
plans and mass production initiatives will be rolled out in phases.
Concurrently, the Company has initiated market entry plans for Taiwan,
including applying for Taiwanese regulatory approval and progressively
establishing sales channels. Market entry efforts will be dynamically
adjusted in alignment with global licensing negotiations and overall
strategic priorities, with the core objective of maximizing the project’s
overall value.
9.New drug development requires long process, vast investments and with
no guarantee in success which may pose investment risks.The investors
are advised to exercise caution and conduct thorough evaluation.: |
|
| 2026/03/02 | 17:48:10 | Medeon is invited to attend the investor conference held by MasterLink Securities | |
| SEQ_NO |
1 |
Date of announcement |
2026/03/02 |
Time of announcement |
17:48:10 |
| Subject |
Medeon is invited to attend the investor conference held by MasterLink Securities |
| Date of events |
2026/03/06
|
To which item it meets |
paragraph 12 |
| Statement |
1.Date of institutional investor conference:2026/03/06
2.Time of institutional investor conference:14:30
3.Location of institutional investor conference:
11F., No. 97, Sec. 2, Dunhua S. Rd., Taipei City (Tunnan Tower, 11F.,
Education and Training Room in MasterLink Securities)
4.Outline of institutional investor conference:
The Company is invited to attend the investor conference held by
MasterLink Securities to outline an overview of the Company’s current
operational status and future development plans.
5.Any other matters that need to be specified:None |
|
| 2026/02/26 | 18:18:17 | Medeon Board of Directors resolved the convening
of the 2026 Annual Shareholders’ Meeting | |
| SEQ_NO |
5 |
Date of announcement |
2026/02/26 |
Time of announcement |
18:18:17 |
| Subject |
Medeon Board of Directors resolved the convening
of the 2026 Annual Shareholders' Meeting |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors’ resolution?G2026/02/26
2.Shareholders meeting date?G2026/06/25
3.Shareholders meeting location?GConference Room, 11F, No. 97, Sec. 2, Dunhua S. Rd., Taipei City,
Taiwan (R.O.C.)
4.Shareholders’ meeting will be held by means of (physical shareholders’ meeting/ hybrid shareholders’ meeting / virtual-only shareholders’ meeting)?Gphysical shareholders’ meeting
5.Cause for convening the meeting (1)?GReport item(s)
(1)?GTo Report the Company’s 2025 Business Report
(2)?GTo Report Audit Committee’s Review Report on the
2025 Financial Statements
(3)?GTo Report the Implementation Status of the Private Placement
(4)?GTo Report the Directors’ Remuneration for the year 2025
(5)?GReport on the Implementation Status of the 2025 Cash Capital Increase Plan
for Strengthening Operations
6.Cause for convening the meeting (2)?GRatification Item(s)
(1)?GTo ratify the Company’s 2025 Business Report and Financial
(2)?GTo Ratify the Company’s 2025 deficit offset proposal
7.Cause for convening the meeting (3)?GDiscussion Item(s)
(1)?GProposal of the private placement by issuing common shares.
(2)?GTo approve the amendment to the Company’s Procedures for
Acquisition or Disposal of Assets.
(3)?GTo release directors or its representatives from
Non-Competition Restrictions
8.Extemporary Motions?G
9.Book closure starting date?G2026/04/27
10.Book closure ending date?G2026/06/25
11.Any other matters that need to be specified?G |
|
| 2026/02/26 | 17:45:45 | Medeon Board of Directors resolved the plan for dividend distribution | |
| SEQ_NO |
4 |
Date of announcement |
2026/02/26 |
Time of announcement |
17:45:45 |
| Subject |
Medeon Board of Directors resolved the plan for dividend distribution |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 14 |
| Statement |
1.Date of the board of directors resolution:2026/02/26
2.Year or quarter which dividends belong to :2025
3.Period which dividends belong to:2025/01/01~2025/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$
per share):0
5.Cash dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders (NT$
per share):0
8.Stock dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10 |
|
| 2026/02/26 | 17:28:37 | Medeon Board of Directors resolved the proposal of private placement to issue additional common shares | |
| SEQ_NO |
2 |
Date of announcement |
2026/02/26 |
Time of announcement |
17:28:37 |
| Subject |
Medeon Board of Directors resolved the proposal of private placement to issue additional common shares |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2026/02/26
2.Types of securities privately placed:The Company’s common shares
3.Counterparties for private placement and their relationship
with the Company:
According to Article 43-6 of the Securities and Exchange Act, the Financial
Supervisory Commission’s Order No. SFB 11220383220 issued on September 12,
2023, and the Directions for Public Companies Conducting Private Placement
of Securities, only the following parties are qualified as specific
investors of the private placement:
A.Insiders of the Company
The reason is that insiders know the operation of the Company very well
and can directly or indirectly contribute to the operation of the
Company. Therefore, placees in this instance of private placement include
the insiders. The list of these insiders is shown below:
a.The list of these insiders and the relation with the Company:
(1) Medeon, Inc. (USA)/ Institutional Director of the Company
(2) Center Laboratories, Inc./ Institutional Director of the Company
(3) Yue Teh Jang/ Representative of Medeon, Inc. of the USA, an
Institutional Director of the Company. Chairman and President of
the Company
(4) Jung-Chin Lin/ Representative of Center Laboratories, Inc.,
an Institutional Director of the Company
(5) Chih-Hsiung Wu/ Representative of Center Laboratories, Inc.,
an Institutional Director of the Company
(6) Chi-Hang Yang/ Independent Director of the Company
(7) Chia-Ying Ma/ Independent Director of the Company
(8) Jien-Wei Yeh/ Independent Director of the Company
(9) Feng Shyang Yang/ Independent Director of the Company
(10) Albert Weng/ Manager of the Company
(11) Greta Chang/ Manager of the Company
(12) Jenny Chen/ Manager of the Company
(13) Pei Chen/ Manager of the Company
(14) Javin Wang/ Accounting Officer of the Company
b.Institutional investors’ Names of the top 10 shareholders and
proportion of shareholding and the relation with the Company:
(1) Medeon, Inc. (USA)
Yue Teh Jang (100%)/ The Chairman of this company is the Chairman
and President of the Company.
(2) Center Laboratories, Inc.
Li Rong Technology Co., Ltd. (9.13%)/ The Chairman of this company
is the spouse of the representative of an Institutional Director of
the Company.
Royal Food Co., Ltd. (5.73%)/ The Chairman of this company is a
representative of an Institutional Director of the Company.
Jason Technology Co., Ltd. (3.51%)/ The Chairman of this company is
the spouse of the representative of an Institutional Director of
the Company.
Yuanta Securities Co., Ltd. in Custody for Mining Investment Fund
of GL Capital Group (2.71%)/ None
Farglory Life Insurance Inc. (1.48%)/ None
You De Investment Consulting Co., Ltd. (1.10%)/ The Chairman
of this company is also the Chairperson of an Institutional
Director of the Company.
Vanguard Total International Stock Index Fund, a series of Vanguard
Star Funds (1.04%)/ None
Mumozi Inc. (1.00%)/ None
Vanguard Emerging Markets Stock Index Fund, a Series of Vanguard
International Equity Index Funds (0.94%)/ None
Yong Lian Co., Ltd. (0.91%)/ None
B.Placees should be strategic investors: It is necessary to bring in
strategic investors that could contribute to the development of the
Company in the future, improvement of financial structure, and upgrade
the profitability of the Company. It is expected that with the assistance
of their capital, technology and knowledge, the Company will be able to
grow steadily in the future.
The Company has not yet pinpointed specific investors for investment. The
Company request the Shareholders’ Meeting to authorize the Board with full
power of attorney to search for the placees.
4.Number of shares or bonds privately placed:
Within the limit of 35,000,000 shares
5.Amount limit of the private placement:
Within the limit of 35,000,000 shares of common stock, the private
placement will be conducted in installments within one year from the date
of the shareholders’ meeting, with the maximum number of installments not
exceeding three.
6.Pricing basis of private placement and its reasonableness:
The reference price for the private placement is set at the higher of the
following two benchmark prices:
A.The average of the closing prices of common shares for one or three or
five (alternative) business days prior to the pricing date, excluding the
ex-rights and dividends of the nil-paid allotment of shares and after
adding back the capital reduction and ex-rights.
B.The average of the closing prices of the common shares for the 30
business days preceding the pricing date, excluding the ex-rights and
dividends of the nil-paid allotment, and after adding back the capital
reduction and ex-rights.
The price of common shares issued in the private placement shall be set at
a level not less than 80% of the reference price. The actual issuance price
of the private placement is proposed to the shareholders’ meeting to
authorize the board of directors to determine the price within a range not
lower than the percentage resolved at the shareholders’ meeting, taking
into account the prevailing market conditions on the pricing date.
7.Use of the funds raised in the private placement:
The purpose of each tranche is to increase working capital, accelerate
product development, invest in subsidiaries and the medical industry, and
develop the Group’s strategic objectives.
8.Reasons for conducting non-public offering:
Considering the timing, convenience and cost of issuance, private placement
of securities can be accomplished quickly and easily. In addition,
securities invested through private placement cannot be transferred in a
period of 3 years after issuing. This helps to assure the long-term stable
relation between the investors and the Company. As such, offering
securities through private placement is adopted.
9.Objections or qualified opinions from independent Board of Directors:None.
10.Actual price determination date:NA
11.Reference price:NA
12.Actual private placement price, and conversion or
subscription price:NA
13.Rights and obligations of these new shares privately placed:
In principle, the rights and obligations of the common shares in the
private placement are the same as those of the Company’s existing common
shares; however, in accordance with the Securities and Exchange Act, the
common shares in the private placement may not be sold within three years
from the date of delivery, except to the parties to whom they are
transferred in accordance with Article 43-8 of the Securities and Exchange
Act. After three years from the date of delivery, the Company intends to
request the shareholders’ meeting to authorize the Board of Directors to
apply to the relevant authorities for a public offering and listing of the
Company’s common shares in accordance with the relevant regulations.
14.Reference date for any additional share exchange, stock
swap, or subscription:NA
15.Possible dilution of equity in case of any additional share
exchange, stock swap, or subscription:NA
16.For additional share exchange or subscription, possible
influence of change in shareholding ratio of TPEx -listed
common shares if all privately placed corporate bonds are
converted and shares subscribed for (no.of TPEx -listed
common shares (a), (a) / outstanding common shares):NA
17.Please explain any countermeasures for lower circulation
in shareholding if the aforesaid estimated no.of TPEx -listed
common shares does not reach 5 million and the ratio does not
reach 25%:NA
18.Any other matters that need to be specified:
(1) The main contents of the private placement plan, including the actual
issue price, the number of shares to be issued, the terms of the issue,
the pricing date, the base date of the capital increase, the planned
projects, the amount to be raised, the estimated progress, the
estimated benefits to be generated, and all other matters related to
the issue plan, in addition to the pricing percentage of the private
placement. The above and in the future, in the event of changes in laws
and regulations, amendments as directed by the competent authorities,
or amendments based on operational evaluations or in response to
objective market conditions, the shareholders’ meeting will also be
requested to authorize the Board of Directors to handle such matters at
its sole discretion.
(2) In connection with the private placement of securities, it is proposed
that the shareholders’ meeting authorize the chairman of the board of
directors or his or her designee to sign and negotiate on behalf of the
Company all contracts and documents relating to the private placement
and to conduct all matters necessary for the Company in connection with
the private placement. |
|
| 2026/02/26 | 17:14:27 | Medeon Board of Directors approved the 2025 consolidated financial reports | |
| SEQ_NO |
1 |
Date of announcement |
2026/02/26 |
Time of announcement |
17:14:27 |
| Subject |
Medeon Board of Directors approved the 2025 consolidated financial reports |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of the board of directors submitted or approved:2026/02/26
2.Date of the audit committee approved:2026/02/26
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2025/01/01~2025/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):419,425
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):58,825
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(722,514)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(719,693)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(719,341)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(668,062)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(7.24)
11.Total assets end of the period (thousand NTD):1,779,793
12.Total liabilities end of the period
(thousand NTD):243,027
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,475,740
14.Any other matters that need to be specified:None |
|
